



Exaflop and Big data approaches against Covid19

Modesto Orozco 02/22/2021

What we learn in one crazy year,...



What we learn in one crazy year,...



HPC is really useful
Centers of Excellence are useful
Computer scientists are useful



The first open data repository of Covid-19



Targets:

3CLpro / Mpro Activity
Inhibition of PLpro Protease Activity
Host Immune Response
Inhibition of Nsp13 Helicase Activity
Blocking SARS-CoV-2 Spike Protein Binding to Human ACE2 Receptor
Inhibiting Cleavage of the SARS-CoV-2 Spike Protein
Inhibition of Formation of the Viral Fusion Core
Inhibition of Viral Polymerases

Proteins:

3CLpro ACE2 BoAT1 E protein Fc receptor Furin Helicase IL6R M protein N protein NSP1
NSP10 NSP11 NSP14 NSP15 NSP16 NSP2 NSP4 NSP6 NSP7 NSP8 NSP9 ORF10 ORF3a ORF6 ORF7a
ORF7b ORF8 PD-1 PLpro RdRP TMPRSS2 fusion core p38 spike virion

Structures:

3CLpro ACE2 BoAT1 E protein Fc receptor Furin Helicase IL6R M protein N protein NSP1
NSP10 NSP11 NSP14 NSP15 NSP16 NSP2 NSP4 NSP6 NSP7 NSP8 NSP9 ORF10 ORF3a ORF6 ORF7a
ORF7b ORF8 PD-1 PLpro RdRP TMPRSS2 fusion core p38 spike virion

Models:

3CLpro ACE2 BoAT1 E protein Fc receptor Furin Helicase IL6R M protein N protein NSP1
NSP10 NSP11 NSP14 NSP15 NSP16 NSP2 NSP4 NSP6 NSP7 NSP8 NSP9 ORF10 ORF3a ORF6 ORF7a
ORF7b ORF8 PD-1 PLpro RdRP TMPRSS2 fusion core p38 spike virion

Therapeutics:

antibody antiviral immunotherapy peptide small molecule

Simulations:

3CLpro ACE2 BoAT1 E protein Fc receptor Furin Helicase IL6R M protein N protein NSP1
NSP10 NSP11 NSP14 NSP15 NSP16 NSP2 NSP4 NSP6 NSP7 NSP8 NSP9 ORF10 ORF3a ORF6 ORF7a
ORF7b ORF8 PD-1 PLpro RdRP TMPRSS2 fusion core p38 spike virion

Links:

ANI-CAS Antiviral Archive ANI-FDA Drugs Archive CORD-19: COVID-19 Open Research Dataset
COV3D: A Coronavirus 3D Structure Database Coronaviruses 101- Focus on Molecular Virology
Drug Repurposing Hub DrugBank database Enamine REAL Space MolPort Open Science Data
Portal PubChem SWEETLEAD Solvation Maps for COVID19-related Protein Targets Structural
Biology Task Force GitHub page Structure models of all mature peptides in 2019-nCoV genome
by C-I-TASSER SuperDRUG The Cambridge Structural Database Tristan Croll ISOLDE COVID-19
models WuXi GalaX1 zinc15 database



Coronavirus nonstructural protein 7

Inhibition of viral polymerases

SARS-CoV-2 nsp7-nsp8-nsp12 RNA polymerase complex in aqueous solution

DESRES

Represented Proteins: [RdRP](#) [NSP7](#) [NSP8](#)

Model: [Files](#) | Source Structure PDBs: [6M71](#) | Visualize: [3DMol1.js](#)

The C- and N-peptide termini capped with amide and acetyl groups respectively. The missing loops in the published structural models were manually built as extended peptide conformation. The missing part of Chain D was built through homology modeling using the structure of SARS-CoV-1 polymerase complex (PDB entry 6NUR). The system was neutralized and salted with NaCl, with a final concentration of 0.15 M.

Simulations:

DESRES-ANTON-10917618 10 μ s simulation of SARS-CoV-2 nsp7-nsp8-nsp12 RNA polymerase complex in aqueous solution

DESRES-ANTON-10917618 10 μ s simulation of SARS-CoV-2 nsp7-nsp8-nsp12 RNA polymerase complex, no water or zinc

SARS-CoV-2 RdRP (NSP12) in complex with NSP7 and two copies of NSP8: ISOLDE refined model

Tristan Croll

Represented Proteins: [RdRP](#) [NSP7](#) [NSP8](#)

Model: [Files](#) | Source Structure PDBs: [6M71](#) | Visualize: [3DMol1.js](#)

Refinement of 6m71 that fixes multiple issues: * Corrects incorrect modeling of both zinc binding sites (originally modeled as disulfides) * Corrects 1-2 dozen rotamer adjustments and peptide flips * Models C-terminal domain of chain D (one of the NSP8s) using well-resolved chain B See [a complete description](#) of the issues remedied by this model.

Simulations:

SARS-CoV-2 RdRp complex (nsp12+2*nsp8+nsp7) + RNA template-primer + ATP model for MD simulations

Vaibhav Modi

University of Jyväskylä -- Department of Chemistry and Nanoscience Center -- Computational Biomolecular Chemistry Group

Represented Proteins: [RdRP](#) [NSP7](#) [NSP8](#)

Model: [Files](#) | Source Structure PDBs: [6NUR](#) [7BTF](#) [7BV2](#) [6YYT](#) | Visualize: [3DMol1.js](#)

Model of the RdRp + RNA + ATP complex of the SARS-CoV-2 with non-covalently bound ATP molecule is built using homology modelling with the SARS-CoV-1 RdRp complex (PDB:6NUR) as template structure (<https://doi.org/10.1038/s41467-019-10280-3>). The modelled structure shows excellent fit (< 0.6 Å) to the SARS-CoV-2 RdRp complex (PDB:6M71) kindly shared with us by Gao et.al. Further, the model of RdRp complex with RNA and ATP molecule in Tri-phosphate form is modelled based on comparative fitting with previously known poliovirus and norovirus structures (with NTP molecule in hydrophobic cleft). The protein-RNA complex with Remdesivir shows excellent fit (< 0.7 Å) with the recently published RdRp complex with RNA template-primer (PDB:7BV2, 6YYT). The fitted models have been equilibrated to perform long MD simulations.

Simulations:

Gromacs 100 ns MD of SARS-CoV-2 RdRp + RNA template-primer + ATP model, All Atom model

SARS-CoV-2 apo-RdRp complex (nsp12+2*nsp8+nsp7) model for MD simulations

Vaibhav Modi

University of Jyväskylä -- Department of Chemistry and Nanoscience Center -- Computational Biomolecular Chemistry Group

Represented Proteins: [RdRP](#) [NSP7](#) [NSP8](#)

Model: [Files](#) | Source Structure PDBs: [6NUR](#) [6M71](#) [7BTF](#) [7BV1](#) | Visualize: [3DMol1.js](#)

Model of the apo-protein form of RdRp complex of the SARS-CoV-2 is built using homology modelling with

Image by

Zhong Ló



Genome-wide structure and function modeling of SARS-COV-2




accession name unit analyses

[MCV1900002](#) SARS spike receptor binding domain bound with FERR ACE2



[MCV1900003](#) Bat-SARS-CoV RATG13 spike receptor binding domain




[MCV1900004](#) Human Angiotensin-converting enzyme 2 (ACE2)




[MCV1900005](#)

[MCV1900006](#) SARS-CoV-2 spike receptor binding domain



[MCV1900007](#) Mutated system of Bat-SARS-CoV RATG13 spike receptor binding domain



Fluctuation PCA Rgyr



HOME BROWSE CONTACT REST API

OVERVIEW

TRAJECTORY

PCA

RGYR

RMSD

FLUCT >

Accession: MCV1900002

DATA IN THIS PAGE

Statistics

Counts


System atoms	Proteins atoms	Proteins residues	Phospholipids	Solvent molecules
136320	12119	757	0	123717
Positive ions	Negative ions			
0	1			

15222 nm³

Adding value to the trajectories

Length	Time step	Number of atoms	Frequency	Time field
200 ns	2 fs	20001	10 ps	Not available
Temperature	Water type	Ensemble	Pressure coupling	Membrane
310 K	Not available	NPT	Isotropic	No

<https://bioexcel-cv19.bsc.es>



MCV1900213 - Trajectory

[DATA IN THIS PAGE](#)

Domains:

Overall

Polymerase

Cofactor 1


Cofactor 2

Cofactor 3

Complex




RTP

RNA



► Trajectory metadata







MCV1900213 - Hydroge


Interaction: Polymer
Polymer
Polymer
Cofactor
Cofactor
Cofactor
RTP - E
RNA - F, G
Complex

[LEU]389:A:618
[SER]520:A:620
[PRO]330:A:5279-[LEU]41:B:15
[THR]328:A:5219-[ASN]42:B:15
[ASP]525:A:8325-[ARG]4:B:14
[ASP]525:A:8327-[ARG]4:B:14
[ASP]276:A:4385-[ARG]25:B:15
[ASP]276:A:4385-[TYR]275:A:4
[ASP]276:A:4385-[ARG]25:B:15
[ASP]276:A:4385-[ARG]25:B:15
[ASP]276:A:4385-[TYR]275:A:4
[ASP]276:A:4385-[ARG]25:B:15
[THR]111:B:16505-[ASN]405:A:6
[TYR]41:B:15736-[TYR]303:A:6
[CYS]326:B:15373-[TYR]275:A:4
[SER]388:A:4149-[TYR]275:A:4
[ASP]271:A:4293-[ARG]25:B:15
[ASN]332:B:15289-[TYR]334:A:5344
[ASP]271:A:4292-[GLN]122:B:16676
[LEU]368:A:5685-[GLN]112:B:14889
[ASP]23:B:15157-[TYR]334:A:5344
[ASN]42:B:15174-[TYR]334:A:5344


Hydrogen bonds





Barcelona
Supercomputing
Center
Centro Nacional de Supercomputación



> Chain F (spike)




> Chain B (spike)



HADDOCK: Meeting the increased demand

The HADDOCK workflow machinery was modified to improve its efficiency and meet the increased demand (allows to run more processes in // - relevant toward exascale).




By now more than 10500 COVID-related runs!!


Template, shape-driven HADDOCKing



Universiteit Utrecht

- Identify template structures
- Transform template compound atoms to dummy atoms
- Dock using restraints from the dummy shape atoms to the conformers without pre-selecting conformers





Workflow Hub



Development of the Workflow Hub for workflows **fast-tracked** for COVID-19

- COVID-19 Virtual **BioHackathon April 2020**
- Community hackathons during 2020
- A pan-project collaboration
- Expanded beyond COVID

>25 **public COVID-19 workflows** identified, curated and registered


- Galaxy, Nextflow, CWL, Snakemake
- Listed on ELIXIR COVID-19 data portal

A catalyst for **community collaboration**

- Workflow creators
- Workflow infrastructure developers

Improved **standards** and **best practices**

- Bioschemas, RO-Crate, CWL, nf-core




<https://covid19.workflowhub.eu>

<https://elixir-europe.org/news/hacking-pandemic>



Develop
HPC tools

RdRNA polymerase




Binding site-driven docking protocol

target	name	atc	score	rank	category	classification
remTP	Remdesivir-triphosphate	NA	-94.866	1	Antivirals	Investigational/Active-Metabolite
DB00923	Ceforanide	J01DC11	-94.804	2	Antiinfectives	Approved
CID23725128	GS-461203	J05AP08,J05AP51,J05AP55,J05AP56	-94.721	3	Antivirals	Approved/Active-Metabolite
DB09050	Ceftolozane	J01DI54	-94.271	4	Antiinfectives	Approved
DB06717	Fosaprepitant	A04AD12	-94.241	5	Other	Approved
DB06590	Ceftaroline-fosamil	J01DI02	-92.098	6	Antiinfectives	Approved
DB11574	Elbasvir	J05AP54	-91.283	7	Antivirals	Approved
CID5271809	favipiravir-RTP	J05AX27	-90.675	8	Antivirals	Approved/Active-Metabolite
DB01632	5-O-phosphono-alpha-D-ribofuranosyl-diphosphate	NA	-90.028	9	NA	Approved
DB09335	Alatrofloxacin	J01MA13	-88.158	10	Antiinfectives	Approved

Showing 1 to 10 of 2,026 entries

Previous 1 2 3 4 5 ... 203 Next







bonvinlab.org/covid



Universiteit Utrecht



RdRNA Polymerase. The core of Covid-19 replication



Complex of NSP7 (83 Aa) & NSP8 (198 Aa) : Primase. NSP12: RNA dependent RNA polymerase


Polimerization mechanism of RdRp SARS-CoV-2

B3LYP/6-311++G**:DFTB3/MM




Very efficient enzyme!

Massive-scale simulations of SARS-CoV-2 proteins




- Markov State Modeling of 100 μ s of simulations of **main protease (Mpro)** revealed alternative loop conformations that produce two distinct states of the active site (Cathrine Bergh, KTH)
- Affects binding in docking studies, improves correlation with SARS-CoV-1 binding assays
- Initiated new collaborations with CINECA and pharma sector (Dompé) that led to EXSCALATE₄CoV project




SARS-CoV-2 (COVID-19) Spike protein trimer


S-protein trimer



RBD complex with human ACE2




Electrostatic potential of RBD



- Responsible for recognition and initial interaction with human cells
- Structure is a trimer with ~1200 amino acids in each individual monomer
- Part of S-protein responsible for binding is called Receptor Binding Domain (RBD)
- Target for the binding found to be human Angiotensin Converting Enzyme 2 (ACE2).
- Target for COVID-19 therapy, through blocking binding towards ACE2

Aptamers design for selective binding




Computationally designed
oligo-DNA based aptamer



Binding mode with SARS-CoV-2 RBD



Experimental binding check



- Synthetic ligands designed to specifically bind with the chosen target.
 - Oligomers of nucleic acids (RNA, DNA)
 - Oligopeptides
 - Hybrid substances which combines nucleic acids with peptides and hydrocarbons.
- Modelling of aptamers allows systematic:
 - Structure prediction
 - Binding sites with estimation of binding affinity
 - Iterative design of the new aptamers using combination of simulations, machine learning techniques and experiments
- The best designed aptamer 31 shows binding affinity close to the much bigger aptamer CoV2-RBD-1C made by *in vitro* evolutionary protocol SELEX




JYVÄSKYLÄN YLIOPISTO
UNIVERSITY OF JYVÄSKYLÄ

Massive exploration of human variability Towards antibody design

ACE2 residues in the interface with SARS-Cov2 RBD were probed in a site saturation mutational scan by means of Rosetta's flex_ddg protocol.

A number of mutations were identified to increase the binding affinity (negative free energy differences in the figure).





SARS-Cov2 RBD mutations

Modeling
studies

Alchemical calculations predict that the probed mutations have only moderate effect (± 1 kcal/mol) on the complex binding affinity in contrast to the previously reported predictions (10.1101/2020.03.15.991844).

The mutations also have moderate effect within the range of ± 2 kcal/mol on the stability of the RBD apo state.





BioExcel Building Blocks software library

Modeling
studies

Develop
HPC tools

HPC



1) Building Blocks

Workflow Managers

<http://mmb.irbbarcelona.org/biobb/>

BioExcel Building Blocks: CLI - Mutations



```
24 # Loading the biobb configuration reader
25 conf = settings.ConfReader(sys.argv[1])
26
27 global_log, _ = fu.get_logs(path=conf.get_working_dir_path())
28 global_prop = conf.get_prop_dic(global_log=global_log)
29 global_paths = conf.get_paths_dic()
30
31 global_log.info("step1_pdb: Download the initial Structure")
32 Pdb(**global_paths["step1_pdb"], properties=global_prop["step1_pdb"]).launch()
33
34 global_log.info("step2_fixsidechain: Modeling the missing heavy atoms in the structure side chains")
35 FixSideChain(**global_paths["step2_fixsidechain"], properties=global_prop["step2_fixsidechain"]).launch()
36
37 for mutation in conf.properties['mutations_list']:
38
39     mut_paths = conf.get_paths_dic(mutation)
40     mut_prop = conf.get_prop_dic(mutation, global_log=global_log)
41
42     mut_paths['step3_mutate']['input_pdb_path'] = global_paths['step2_fixsidechain']['output_pdb_path']
43
44     global_log.info("step3_mutate: Modeling a particular residue mutation")
45     Mutate(**mut_paths["step3_mutate"], properties=mut_prop["step3_mutate"]).launch()
46
47     global_log.info("step4_pdb2gmx: Generate the topology")
48     Pdb2gmx(**mut_paths["step4_pdb2gmx"], properties=mut_prop["step4_pdb2gmx"]).launch()
```





```
7
8 mutations_list: ["A:Arg5Ala", "A:Arg5Gly", "A:Arg5Lys"]
9
10 step1_pdb:
11   paths:
12     output_pdb_path: structure.pdb
13   properties:
14     pdb_code: 1aki
```

PyCOMPSs automatic parallelization

```
print 'step2: mmbuniprot -- Get mutations'
mmbuniprot = uniprot.MmbVariants(prop['pdb_code'])
mutations = mmbuniprot.fetch_variants()

for mut in mutations:
    mut_path = cdirc(wd, mut)



    print 'step3: scw -- Model mutation'
    scw_path = cdirc(mut_path, 'step3_scw')
    scw_pdb = opj(scw_path, prop['mutated_pdb'])
    scw = scwrl.Scwrl4(mmbpdb_pdb, scw_pdb, mut, scwrl_path=scwrl_path)
    scw_pdb2 = scw.launchPyCOMPSs()
```






The COVID-19 bbb workflow team





PMX BBB workflows





Crooks theorem



COVID-19: infective process







- ICEI/Fenix
PRACE
Access

PRACE-ICEI Call for Proposals Application Form

Project name	BioExcel biomolecular simulation workflows-3
Research field	Life Sciences, Biomolecular simulation, Structural Bioinformatics, Molecular Dynamics, Free energy, Docking

Where does SARS-Cov2 come from and where is it going?

Phylogenetic Tree for the whole SPIKE protein



0,060

- BtKY72/Bat/Kenya/2007_rhinolohpus_spp
- SARS-CoV-2/UniSR1
- hCoV/19/bat/Yunnan/RaTG13/2013_affinis
- hCoV-19/pangolin/Guangxi/P5L/2017
- hCoV-19/pangolin/Guangxi/P1E/2017
- hCoV-19/pangolin/Guangxi/P5E/2017
- hCoV/19/pangolin/Guangdong/1/2019[EPI_ISL_410721]
- SARS_coronavirus/HC/GZ/81/03/civet/china/2003
- SARS_coronavirus/PC4-227/civet/china/2004
- SARS_coronavirus/PC4-13/civet/china/2004
- SARS-related_HC/GZ/32/03/Civet/China/2003
- SARS-related_CFB/SZ/94/03/Badger/China/2003
- SARS_coronavirus/HC/SZ/79/03/civet/china/2003
- SARS_Urbani
- SARS-related_SZ16/Civet/Hong_Kong/2003
- Rs4874/Bat/China/2013_sinicus
- NA/WIV16/Bat/China/2013_sinicus
- Rs4231/Bat/China/2013_sinicus
- Rs9401/Bat/China/2015_10_16_sinicus
- Rs7327/Bat/China/2014_10_24_sinicus
- BtRs-BetaCoV/YN2018B_China_affinis
- WIV1/Bat/China/2012_sinicus
- Rs3367/Bat/China/2012_sinicus
- Rs4084/Bat/China/2012_sinicus
- RsSHC014/Bat/China/2011_sinicus
- LYRa11/Bat/China/2011_affinis



RatG13 a virus from bat is the closest analog to SARS_Cov2

But RatG13 and SARS_Cov2 RBD are completely different

- BtKY72/Bat/Kenya/2007_rhinolohpus_spp
- SARS-CoV-2/UniSR1
- hCoV/19/bat/Yunnan/RaTG13/2013_affinis
- hCoV-19/pangolin/Guangxi/P5L/2017




2	● Acidic	1
4	● Basic	2
9	● Polar	10
4	○ Non-Polar	6







No zoonotic barrier!




SARS_Cov2




$\Delta G = -0.3$ kcal/mol favoring SARS-Cov2 binding



RATG13






		1	10	20	30	40	50	60	70	80	8																																																																					
affinis_MT394206.f	1	S	T	E	D	R	A	K	I	F	L	D	N	F	N	K	E	A	E	L	S	Y	Q	S	S	L	A	S	W	E	N	T	N	I	S	D	E	N	V	Q	K	M	D	E	A	G	A	K	M	S	A	F	Y	E	E	Q	S	K	L	A	K	N	T	P	L	E	E	I	Q	T	V	P	V	K	L	Q	L	Q	Q	Q
affinis_MT394206.f	1	S	T	E	D	R	A	K	I	F	L	D	N	F	N	K	E	A	E	L	S	Y	Q	S	S	L	A	S	W	E	N	T	N	I	S	D	E	N	V	Q	K	M	D	E	A	G	A	K	M	S	A	F	Y	E	E	Q	S	K	L	A	K	N	T	P	L	E	E	I	Q	T	V	P	V	K	L	Q	L	Q	Q	Q
affinis_MT394220.f	1	S	T	E	D	R	A	K	I	F	L	D	N	F	N	K	E	A	E	L	S	Y	Q	S	S	L	A	S	W	E	N	T	N	I	S	D	E	N	V	Q	K	M	D	E	A	G	A	K	M	S	A	F	Y	E	E	Q	S	K	L	A	K	N	T	P	L	E	E	I	Q	T	V	P	V	K	L	Q	L	Q	Q	Q
affinis_MT394221.f	1	S	T	E	D	R	A	K	I	F	L	D	N	F	N	K	E	A	E	L	S	Y	Q	S	S	L	A	S	W	E	N	T	N	I	S	D	E	N	V	Q	K	M	D	E	A	G	A	K	M	S	A	F	Y	E	E	Q	S	K	L	A	K	N	T	P	L	E	E	I	Q	T	V	P	V	K	L	Q	L	Q	Q	Q
affinis_MT394212.f	1	S	T	E	D	R	A	K	I	F	L	D	N	F	N	K	E	A	E	L	S	Y	Q	S	S	L	A	S	W	E	N	T	N	I	S	D	E	N	V	Q	K	M	D	E	A	G	A	K	M	S	A	F	Y	E	E	Q	S	K	L	A	K	N	T	P	L	E	E	I	Q	T	V	P	V	K	L	Q	L	Q	Q	Q
affinis_MT394225.f	1	S	T	E	D	R	A	K	I	F	L	D	N	F	N	K	E	A	E	L	S	Y	Q	S	S	L	A	S	W	E	N	T	N	I	S	D	E	N	V	Q	K	M	D	E	A	G	A	K	M	S	A	F	Y	E	E	Q	S	K	L	A	K	N	T	P	L	E	E	I	Q	T	V	P	V	K	L	Q	L	Q	Q	Q
affinis_MT394213.f	1	S	T	E	D	R	A	K	I	F	L	D	N	F	N	K	E	A	E	L	S	Y	Q	S	S	L	A	S	W	E	N	T	N	I	S	D	E	N	V	Q	K	M	D	E	A	G	A	K	M	S	A	F	Y	E	E	Q	S	K	L	A	K	N	T	P	L	E	E	I	Q	T	V	P	V	K	L	Q	L	Q	Q	Q
affinis_MT394214.f	1	S	T	E	D	R	A	K	I	F	L	D	N	F	N	K	E	A	E	L	S	Y	Q	S	S	L	A	S	W	E	N	T	N	I	S	D	E	N	V	Q	K	M	D	E	A	G	A	K	M	S	A	F	Y	E	E	Q	S	K	L	A	K	N	T	P	L	E	E	I	Q	T	V	P	V	K	L	Q	L	Q	Q	Q
affinis_MT394205.f	1	S	T	E	D	R	A	K	I	F	L	D	N	F	N	K	E	A	E	L	S	Y	Q	S	S	L	A	S	W	E	N	T	N	I	S	D	E	N	V	Q	K	M	D	E	A	G	A	K	M	S	A	F	Y	E	E	Q	S	K	L	A	K	N	T	P	L	E	E	I	Q	T	V	P	V	K	L	Q	L	Q	Q	Q
affinis_MT394211.f	1	S	T	E	D	R	A	K	I	F	L	D	N	F	N	K	E	A	E	L	S	Y	Q	S	S	L	A	S	W	E	N	T	N	I	S	D	E	N	V	Q	K	M	D	E	A	G	A	K	M	S	A	F	Y	E	E	Q	S	K	L	A	K	N	T	P	L	E	E	I	Q	T	V	P	V	K	L	Q	L	Q	Q	Q
affinis_MT394212.f	1	S	T	E	D	R	A	K	I	F	L	D	N	F	N	K	E	A	E	L	S	Y	Q	S	S	L	A	S	W	E	N	T	N	I	S	D	E	N	V	Q	K	M	D	E	A	G	A	K	M	S	A	F	Y	E	E	Q	S	K	L	A	K	N	T	P	L	E	E	I	Q	T	V	P	V	K	L	Q	L	Q	Q	Q
affinis_MT394217.f	1	S	T	E	D	R	A	K	I	F	L	D	N	F	N	K	E	A	E	L	S	Y	Q	S	S	L	A	S	W	E	N	T	N	I	S	D	E	N	V	Q	K	M	D	E	A	G	A	K	M	S	A	F	Y	E	E	Q	S	K	L	A	K	N	T	P	L	E	E	I	Q	T	V	P	V	K	L	Q	L	Q	Q	Q
affinis_MT394218.f	1	S	T	E	D	R	A	K	I	F	L	D	N	F	N	K	E	A	E	L	S	Y	Q	S	S	L	A	S	W	E	N	T	N	I	S	D	E	N	V	Q	K	M	D	E	A	G	A	K	M	S	A	F	Y	E	E	Q	S	K	L	A	K	N	T	P	L	E	E	I	Q	T	V	P	V	K	L	Q	L	Q	Q	Q
affinis_MT394219.f	1	S	T	E	D	R	A	K	I	F	L	D	N	F	N	K	E	A	E	L	S	Y	Q	S	S	L	A	S	W	E	N	T	N	I	S	D	E	N	V	Q	K	M	D	E	A	G	A	K	M	S	A	F	Y	E	E	Q	S	K	L	A	K	N	T	P	L	E	E	I	Q	T	V	P	V	K	L	Q	L	Q	Q	Q
affinis_MT394223.f	1	S	T	E	D	R	A	K	I	F	L	D	N	F	N	K	E	A	E	L	S	Y	Q	S	S	L	A	S	W	E	N	T	N	I	S	D	E	N	V	Q	K	M	D	E	A	G	A	K	M	S	A	F	Y	E	E	Q	S	K	L	A	K	N	T	P	L	E	E	I	Q	T	V	P	V	K	L	Q	L	Q	Q	Q
affinis_MT394207.f	1	S	T	E	D	R	A	K	I	F	L	D	N	F	N	K	E	A	E	L	S	Y	Q	S	S	L	A	S	W	E	N	T	N	I	S	D	E	N	V	Q	K	M	D	E	A	G	A	K	M	S	A	F	Y	E	E	Q	S	K	L	A	K	N	T	P	L	E	E	I	Q	T	V	P	V	K	L	Q	L	Q	Q	Q
affinis_MT394209.f	1	S	T	E	D	R	A	K	I	F	L	D	N	F	N	K	E	A	E	L	S	Y	Q	S	S	L	A	S	W	E	N	T	N	I	S	D	E	N	V	Q	K	M	D	E	A	G	A	K	M	S	A	F	Y	E	E	Q	S	K	L	A	K	N	T	P	L	E	E	I	Q	T	V	P	V	K	L	Q	L	Q	Q	Q
affinis_MT394210.f	1	S	T	E	D	R	A	K	I	F	L	D	N	F	N	K	E	A	E	L	S	Y	Q	S	S	L	A	S	W	E	N	T	N	I	S	D	E	N	V	Q	K	M	D	E	A	G	A	K	M	S	A	F	Y	E	E	Q	S	K	L	A	K	N	T	P	L	E	E	I	Q	T	V	P	V	K	L	Q	L	Q	Q	Q
affinis_MT394224.f	1	S	T	E	D	R	A	K	I	F	L	D	N	F	N	K	E	A	E	L	S	Y	Q	S	S	L	A	S	W	E	N	T	N	I	S	D	E	N	V	Q	K	M	D	E	A	G	A	K	M	S	A	F	Y	E	E	Q	S	K	L	A	K	N	T	P	L	E	E	I	Q	T	V	P	V	K	L	Q	L	Q	Q	Q




Be ready for further zoonotic transmission






PMX BB Workflow (human polymorphisms)

Modeling studies




<i>Variants</i>	<i>Mutation</i>	<i>Allele frequency</i>	<i>ddG (Kcal/mol)</i>
rs73635825	S19P	3,13E-04	-
rs1299103394	K26E	5,45E-06	0,89
rs4646116	K26R	3,88E-03	-1,1
rs781255386	T27A	1,09E-05	0,1
rs778500138	E35D	N/A	0,1
rs1348114695	E35K	1,64E-05	4,25
rs146676783	E37K	3,90E-05	7,3
rs755691167	K68E	1,09E-05	2,36
rs766996587	M82I	2,44E-05	1,44
rs759134032	P84T	5,47E-06	-
rs143936283	E329G	3,44E-05	0,36
rs961360700	D355N	1,17E-05	3,48
rs1396769231	M383T	N/A	-1,24
rs762890235	P389H	3,83E-05	-
rs1238146879	P426A	5,47E-06	-
rs1316056737	D427Y	1,09E-05	0,38
rs1016777825	R559S	N/A	-2,14



Modeling
studies

Exploring virus



SARS-Cov2 is selecting
mutations favoring binding!

RBD position	original	variation	frequency	location	Fold-x ddG (Kcal/mol)	pmx ddG (Kcal/mol)	
439	N	K	213	Scotland	-1,88	-3,85	
444	K	R	1	Australia	-0,39	-0,77	
446	G	A	3		2,45	0,45	
445	V	I	1		-0,63	0,07	
446	G	S	3	Australia/England	3,39	0,53	
446	G	V	3		4,07	-0,22	
455	L	F	1		3,22	2,48	
456	F	L	1		2,61	1,55	
475	A	V	4	USA	1,81	-1,71	
476	G	S	19	USA (1 in Belgium)	1,9	0,31	0.2
478	T	I	65	England	-0,85	-0,06	
483	V	A	30	USA	-0,2	0,07	-0.5
483	V	I	2	UK	0,04	0,03	
483	V	F	5	Spain	-0,2	0,21	
484	E	A	1		1,06	-	
490	F	S	3	England	1,11	0,25	
490	F	L	2	Australia	0,64	-0,3	
494	S	P	3	England	-	-	
495	Y	N	1	Luxembourg	5,25	1,39	
503	V	F	1	USA	-0,71	0,19	



MAX-PLANCK-GESELLSCHAFT



**Barcelona
Supercomputing
Center**
Centro Nacional de Supercomputación



**IRB
BARCELONA**

INSTITUTE
FOR RESEARCH
IN BIOMEDICINE



BioExcel Partners 2019



Horizon 2020
European Union Funding
for Research & Innovation

BioExcel is funded by the European Union
Horizon 2020 program under grant
agreements 675728 and 823830.